Q&A: What AI Reveals That Scientists Could Not See Before

Artificial intelligence (AI) is no longer a peripheral tool in biopharma but rather is rapidly becoming embedded in nearly every stage of the drug development continuum, from early target identification through clinical trial design, manufacturing, and post-market expansion. But with that integration comes a set of questions that are more complex than any algorithm alone can answer, such as, what does responsible deployment look like? Who is accountable when a model is wrong? And does AI actually move the needle on clinical and manufacturing success?